Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1998 Jun;42(6):1355-60.
doi: 10.1128/AAC.42.6.1355.

Lysostaphin treatment of experimental methicillin-resistant Staphylococcus aureus aortic valve endocarditis

Affiliations

Lysostaphin treatment of experimental methicillin-resistant Staphylococcus aureus aortic valve endocarditis

M W Climo et al. Antimicrob Agents Chemother. 1998 Jun.

Abstract

The emergence of clinical isolates of methicillin-resistant Staphylococcus aureus with reduced susceptibility to vancomycin has prompted a search for new and novel therapeutic agents active against S. aureus. Lysostaphin, a peptidase produced by Staphylococcus simulans, specifically cleaves the glycine-glycine bonds unique to the interpeptide cross-bridge of the S. aureus cell wall. The effectiveness of various regimens of dosing with intravenous lysostaphin was compared to that of vancomycin in the rabbit model of aortic valve endocarditis caused by a clinical methicillin-resistant S. aureus isolate. All animals were treated for a total of 3 days. The most active regimen, lysostaphin given three times daily, produced sterile vegetations in 10 of 11 treated rabbits, with a mean reduction in vegetation bacterial counts of 8.5 log10 CFU/g compared to the counts in the untreated controls. In contrast, vancomycin given twice daily sterilized no vegetations and reduced vegetation bacterial counts by only 4.8 log10 CFU/g. Lysostaphin given once daily was less effective, reducing mean vegetation bacterial counts by only 3.6 log10 CFU/g, but the combination of lysostaphin once daily and vancomycin twice daily reduced the mean vegetation bacterial density by 7.5 log10 CFU/g, a result that was significantly better than that for either regimen alone (P < 0.05). Lysostaphin was well tolerated by the rabbits, with no evidence of immunological reactions following up to 9 weeks of intravenous administration. We conclude that lysostaphin given alone or in combination with vancomycin is more effective in the treatment of experimental methicillin-resistant S. aureus aortic valve endocarditis than vancomycin alone.

PubMed Disclaimer

Figures

FIG. 1
FIG. 1
Clearance of bacteremia in the rabbit model of experimental aortic valve endocarditis following the administration of single doses of lysostaphin (•) and vancomycin (▪). For the three rabbits in each group, means and ranges of bacterial counts in blood are given.

Similar articles

Cited by

References

    1. Bayer A S, Lam K. Efficacy of vancomycin plus rifampin in experimental aortic-valve endocarditis due to methicillin-resistant Staphylococcus aureus: in vitro-in vivo correlations. J Infect Dis. 1985;151:157–165. - PubMed
    1. Boyce J M, Medeiros A A. Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, D.C: American Society for Microbiology; 1997. Clinical isolates of methicillin-resistant Staphylococcus aureus from the United States with subpopulations of cells with reduced susceptibility to vancomycin, abstr. LB-15; p. 6.
    1. Bramley A J, Foster R. Effects of lysostaphin on Staphylococcus aureus infections of the mouse mammary gland. Res Vet Sci. 1990;49:120–121. - PubMed
    1. Centers for Disease Control and Prevention. Update: Staphylococcus aureus with reduced susceptibility to vancomycin—United States, 1997. Morbid Mortal Weekly Rep. 1997;46:813–815. - PubMed
    1. Chambers H F. In vitro and in vivo antistaphylococcal activities of L-695,256, a carbapenem with high affinity for the penicillin-binding protein PBP 2a. Antimicrob Agents Chemother. 1995;39:462–466. - PMC - PubMed

Publication types

MeSH terms